Eagle PharmaceuticalsEGRX
13F holders, Q4 2024 (December 31)9holders −56
0new positions
56sold out
$0.49avg. 13F price*
At the end of Q4 2024, 9 institutions reported holding Eagle Pharmaceuticals Inc. (EGRX) in their 13F filings, down 56 from Q3 2024. 0 opened new positions and 56 sold out. The largest holders were XTX Topco Ltd ($12K), Simplex Trading, LLC ($9K) and Barclays PLC ($7K).
- Company
- Eagle Pharmaceuticals Inc.
- CUSIP
- 269796108
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 56 | $31.5M |
All 13F filers, Q3 2024 → Q4 2024: 10,964 shares bought and 8,431,883 shares sold, net −8,420,919 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| XTX Topco Ltd | 0.00% | Add +5.2% | 23,594 | $12K |
| Simplex Trading, LLC | 0.00% | Add +117.4% | 18,162 | $9K |
| Barclays PLC | 0.00% | Reduce -5.4% | 14,233 | $7K |
| Stanley-Laman Group, Ltd. | 0.00% | No change | 12,000 | $6K |
| Acadian Asset Management LLC | 0.00% | No change | 7,155 | $3K |
| Russell Investments Group, Ltd. | 0.00% | Reduce -4.2% | 3,411 | $2K |
| Archer Investment Corp | 0.00% | No change | 350 | $175 |
| Credit Agricole S A | 0.00% | No change | 36 | $18 |
| Farther Finance Advisors, LLC | 0.00% | Reduce -45.3% | 35 | $18 |
"% of holder's portfolio" is EGRX's weight in each manager's 13F, not the share of Eagle Pharmaceuticals Inc. the manager owns.